Colorectal cancer: exercise improves fitness, but the optimal dose remains uncertain

Trials focused on several dimensions of health

The researchers pooled 26 randomized trials of exercise interventions in patients with colorectal cancer. The programs lasted at least four weeks. The literature search covered five databases.

The review examines six health domains and includes 266 effect estimates. The abstract mainly details findings on cardiorespiratory fitness and muscular capabilities. It does not specify the comparators in each trial or the breakdown of patients by cancer stage or treatments received.

A physical benefit, not evidence of an effect on cancer progression

The pooled results show statistically significant improvements in cardiorespiratory fitness, with an effect size of 0.35, and muscular capabilities, with an effect size of 0.45. These values are not percentage improvements and cannot predict how much a particular person will benefit.

The abstract provides neither confidence intervals nor an explanation of what these results mean in terms of concrete changes in daily life. It also reports no findings on recurrence or survival. Improving fitness therefore does not, on its own, demonstrate a change in the course of cancer.

Timing in relation to treatment seems to matter

Subgroup analyses suggest that prehabilitation interventions, before treatment, produce the best results. During active treatment, the authors describe a downward trend followed by a rebound over time.

Analyses exploring exercise parameters also suggest threshold effects and benefits from sustained participation at moderate to high intensity. But these comparisons between studies are not enough to establish an optimal dose for each patient. The abstract provides no numerical threshold that can be directly applied.

A review is not a prescription

The authors assessed risks of bias and the quality of the evidence without reporting the detailed results in the abstract. Heterogeneity, adverse events, funding and conflicts of interest cannot be verified from this excerpt.

The useful finding is therefore more limited than identifying an ideal dose: exercise appears to improve certain physical capabilities in this population, while adapting it to different phases of treatment remains a matter for individual assessment.

What we can take away

This review supports a fitness benefit from exercise in patients with colorectal cancer. It does not establish a universal dose or allow conclusions about an effect on survival.